Author

Qiongdan Hu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Network pharmacology and experimental verification reveal the mechanism of hederagenin in suppressing podocyte injury in focal segmental glomerular sclerosis.

BACKGROUND Podocyte injury is a pivotal driver of chronic kidney disease (CKD) progression in focal segmental glomerulosclerosis (FSGS). Although hederagenin (HDG) has shown promise in the treatment of CKD, its specific protective effects against podocyte injury in FSGS, along with its underlying pharmacological mechan...

Xinyuan Tian, Rang-yue Han, Xiao-Jiao Gu et al. · Clinical Nephrology · 0 citations

Review Jul 2026

Chronic kidney disease‑associated encephalopathy: Clinical features, pathomechanisms and emerging therapeutic strategies (Review).

The present review systematically outlines the clinical manifestations, core pathogenic mechanisms and emerging therapeutic strategies for CKD‑associated encephalopathy, and the targeted interventions on the gut‑kidney‑brain axis.

Nanling Zeng, Ling Jiang, Yang Zhang et al. · Molecular Medicine Reports · 0 citations

Review Open access Aug 2026

Research progress on BTG2 in non-tumor diseases (Review)

This review systematically synthesizes advances in the pivotal, context-dependent roles of BTG2 in non-tumor pathologies, including fibrotic, neurological, cardiovascular, inflammatory, metabolic and other systemic diseases.

Shu-Ling Li, Xiao-Mei Liu, Zheng Zhang et al. · International Journal of Mol... · 0 citations